Corcept Therapeutics (CORT) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is CORT's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metab…

Corcept Therapeutics Incorporated (NASDAQ: CORT - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eight ratings firms that are currently covering the firm, MarketBeat.com reports. One equities…

Corcept's Q3 earnings and revenues beat estimates, driven by strong Lifyorli uptake and higher Korlym sales, as the company advances its pipeline.…

Corcept Therapeutics Incorporated (CORT) Q3 2026 Earnings Call Transcript…

Corcept Therapeutics NASDAQ: CORT reported third-quarter 2026 revenue of $340.5 million, up 33% from the prior quarter and 64% from a year earlier, as growth in its endocrinology business and the launch of ovarian cancer…

Corcept Therapeutics (CORT) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.16 per share a year ago.…

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metab…

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metab…

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metab…

CORT banks on newly approved drug, Lifyorli, while potential new approvals and clinical studies could help diversify revenues beyond Korlym.…

Corcept Therapeutics Incorporated (NASDAQ: CORT - Get Free Report) Director James Wilson sold 10,000 shares of the company's stock in a transaction dated Thursday, October 15th. The shares were sold at an average price o…

First Citizens Bank and Trust Co. trimmed its holdings in Corcept Therapeutics Incorporated (NASDAQ: CORT) by 62.0% in a recent quarter, according to its most recent disclosure with the Securities and Exchange Commission…

ROST, ROKU, APA, CORT and HALO are five non-tech Nasdaq stocks riding strong growth trends and rising earnings estimates, positioning them for potential gains in Q4.…

As inflation surges on rising energy costs, CAH, UNH and CORT stand out as low-beta healthcare stocks with strong expected earnings growth and defensive appeal.…

Shares of Corcept Therapeutics Incorporated (NASDAQ: CORT - Get Free Report) have been given an average rating of "Moderate Buy" by the eight research firms that are covering the company, Marketbeat.com reports. One equi…

Xeris Biopharma (NASDAQ: XERS - Get Free Report) and Corcept Therapeutics (NASDAQ: CORT - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on th…

ABT, CORT, PGEN and BHC offer low-beta healthcare exposure as rate-hike fears and market volatility persist.…

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metab…

Corcept's Lifyorli plus nab-paclitaxel wins a positive CHMP opinion for platinum-resistant ovarian cancer, with an EC decision expected in Q4 2026.…

Corcept Therapeutics Incorporated (NASDAQ: CORT - Get Free Report) insider Roberto Vieira sold 296 shares of the firm's stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of …

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metab…

Corcept's Korlym sales rise 6.2% in H1 2026 as demand grows, while Lifyorli's launch offers a path to diversify revenues.…

Institutions keep buying Corcept Therapeutics Incorporated (CORT) shares in big volumes, sending them up 1,016% since 2017 and on the cusp of joining the S&P MidCap 400 index.…
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Feb 23. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

